Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?

dc.creatorSolar, Héctor
dc.creatorDoeyo, Mariana
dc.creatorOrtega, Mariana
dc.creatorDe Barrio, Silvia
dc.creatorOlano, Estela
dc.creatorMoreira, Eduardo
dc.creatorBuncuga, Martín Gonzalo
dc.creatorManzur, Alejandra Marisa
dc.creatorCrivelli, Adriana
dc.creatorGondolesi, Gabriel Eduardo
dc.date2021-08
dc.date.accessioned2023-08-31T00:29:47Z
dc.date.available2023-08-31T00:29:47Z
dc.identifierhttp://hdl.handle.net/11336/182166
dc.identifierSolar, Héctor; Doeyo, Mariana; Ortega, Mariana; De Barrio, Silvia; Olano, Estela; et al.; Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?; SAGE Publications; Journal of Parenteral and Enteral Nutrition; 45; 5; 8-2021; 1072-1082
dc.identifier0148-6071
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8543486
dc.descriptionBackground: Teduglutide, a semisynthetic analogue of glucagon-like peptide-2 (sGLP-2), increases intestinal absorption of fluids and nutrients, reducing the need for parenteral nutrition (PN). This report aims to describe our experience with sGLP-2 in a cohort of adult patients with short-bowel syndrome. Methods: This is a prospective observational study on adult patients initially evaluated in our specialized intestinal rehabilitation program that received sGLP-2 from June 2014 to March 2020. Results: Autologous gastrointestinal reconstruction surgery (AGIRS) was performed in 108 patients; 68.5% (74 of 108) achieved intestinal sufficiency with standard medical therapy. Seventeen patients were treated with sGLP-2; 66.5% (8 of 12) received treatment for a mean time of 25.8 weeks (3.4–54.0) and could suspend PN. One patient reinitiated treatment due to renal lithiasis and acute renal failure. Currently, 7 of 12 patients (53.8%) continue without PN for a mean time of 165.6 weeks. Volume, energy, and days of PN were reduced in all patients. No serious adverse events were registered. Four of 7 patients (57.1%) who discontinued PN could also discontinue sGLP-2. Therefore, the use of sGLP-2 increased the overall success rate of PN independency after AGIRS to 76% (82 of 108). Conclusion: This study confirmed that sGLP-2 should be considered as part of the standard therapy for postsurgical medical rehabilitation treatment in patients with chronic intestinal failure. We add to the current knowledge that some patients can discontinue both PN and sGLP-2 in the long term, achieving complete recovery of their quality of life.
dc.descriptionFil: Solar, Héctor. Universidad Favaloro; Argentina
dc.descriptionFil: Doeyo, Mariana. Universidad Favaloro; Argentina
dc.descriptionFil: Ortega, Mariana. Universidad Favaloro; Argentina
dc.descriptionFil: De Barrio, Silvia. Hospital San Martín; Argentina
dc.descriptionFil: Olano, Estela. Hospital Maciel; Uruguay
dc.descriptionFil: Moreira, Eduardo. Hospital Maciel; Uruguay
dc.descriptionFil: Buncuga, Martín Gonzalo. Delta Hospital; Argentina
dc.descriptionFil: Manzur, Alejandra Marisa. Gobierno de la Provincia de Mendoza. Hospital Central de Mendoza.; Argentina
dc.descriptionFil: Crivelli, Adriana. Universidad Favaloro; Argentina
dc.descriptionFil: Gondolesi, Gabriel Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherSAGE Publications
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jpen.1983
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/10.1002/jpen.1983
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subjectGLP2
dc.subjectHOME NUTRITION SUPPORT
dc.subjectINTESTINAL FAILURE
dc.subjectPARENTERAL NUTRITION
dc.subjectREHABILITATION
dc.subjectSHORT BOWEL SYNDROME
dc.subjectSURGERY
dc.subjectTEDUGLUTIDE
dc.subjecthttps://purl.org/becyt/ford/3.2
dc.subjecthttps://purl.org/becyt/ford/3
dc.titlePostsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución